Page 22 - ப்ராடக்ட்ஸ் நிறுவனம் இணை லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Xinhua Commentary: Vaccine slur more dangerous than virus - Xinhua

Xinhua Commentary: Vaccine slur more dangerous than virus - Xinhua
xinhuanet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from xinhuanet.com Daily Mail and Mail on Sunday newspapers.

Products institute co ltdChina national biotec groupWorld health organizationப்ராடக்ட்ஸ் நிறுவனம் இணை லிமிடெட்சீனா தேசிய பயோடெக் குழுஉலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்

Chinese vaccine proves 79 34 pct effective against COVID-19 in phase-3 study

Chinese vaccine proves 79.34 pct effective against COVID-19 in phase-3 study Xinhua | Updated: 2020-12-30 17:59 Share CLOSE A coronavirus disease (COVID-19) Human Immunoglobulin for Intravenous Injection from China National Biotec Group (CNBG). [Photo/Agencies] BEIJING - A Chinese inactivated vaccine shows 79.34 percent efficacy against COVID-19, according to the interim results of the phase-3 clinical trials unveiled by its developer Wednesday. The inactivated vaccine is developed by the Beijing Biological Products Institute Co Ltd under the China National Biotec Group, which is affiliated with Sinopharm. After a two-dose inoculation procedure, the vaccine receivers all produced high titers of antibodies, and the seroconversion rate of neutralizing antibodies reached 99.52 percent.

Cui gangZheng zhongweiProducts institute co ltdSinovac biotechChina national medical products administrationChina national biotec groupNational health commissionWorld health organizationHuman immunoglobulinIntravenous injectionBeijing biological products institute co ltdNational medical productsசுத்தி கும்பல்ப்ராடக்ட்ஸ் நிறுவனம் இணை லிமிடெட்சீனா தேசிய பயோடெக் குழுதேசிய ஆரோக்கியம் தரகு

Xinhua Commentary: Vaccine slur more dangerous than virus - China News

2020-12-30 10:05:29 GMT2020-12-30 18:05:29(Beijing Time) Xinhua English BEIJING, Dec. 30 (Xinhua) China s vaccine companies are working tirelessly to advance COVID-19 vaccine research and have achieved remarkable outcomes, with a vaccine developed by a unit of the China National Biotec Group (CNBG) 79.34 percent effective. The efficacy rate, based on the interim results of phase-three clinical trials, means a step closer to victory over the virus and another V-shaped recovery, the V here standing for vaccine. China is not racing against any other country to develop its COVID-19 vaccines, but against time. Safety and efficacy are the top priorities. In fact, no country can afford a hasty rollout of vaccines if speed or other considerations outweigh safety and effectiveness. China is not an exception. Be it epidemic control and prevention or the process of vaccine development, China has always put safety and efficacy first.

Products institute co ltdChina national biotec groupWorld health organizationப்ராடக்ட்ஸ் நிறுவனம் இணை லிமிடெட்சீனா தேசிய பயோடெக் குழுஉலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்

Live COVID-19 updates: India reports 20,549 new COVID-19 cases, tally rises to 10,244,852

Live COVID-19 updates: India reports 20,549 new COVID-19 cases, tally rises to 10,244,852
china.org.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from china.org.cn Daily Mail and Mail on Sunday newspapers.

Krung thep mahanakhonSoult ukpyolsiSouth koreaKyonggi doSamut sakhonTaweesin visanuyothinProducts institute co ltdChina national biotec groupSituation administrationதெற்கு கொரியாப்ராடக்ட்ஸ் நிறுவனம் இணை லிமிடெட்சீனா தேசிய பயோடெக் குழு

Chinese Covid-19 vaccine found 79% effective in late stage trial

Chinese Covid-19 vaccine found 79% effective in late stage trial By IANS | Published on Wed, Dec 30 2020 17:03 IST | 0 Views Chinese Covid-19 vaccine found 79% effective in late stage trial. Image Source: IANS News Beijing, Dec 30 : A Chinese inactivated vaccine shows 79.34 percent efficacy against COVID-19, according to the interim results of the phase-3 clinical trials unveiled by its developer on Wednesday. The inactivated vaccine has been developed by the Beijing Biological Products Institute Co., Ltd. under the China National Biotec Group (CNBG), which is affiliated to Sinopharm, Xinhua news agency reported. After a two-dose inoculation procedure, the vaccine receivers all produced high titers of antibodies, and the seroconversion rate of neutralising antibodies reached 99.52 percent.

Products institute co ltdChina national biotec groupChina national medical products administrationWorld health organizationNational medical products administrationப்ராடக்ட்ஸ் நிறுவனம் இணை லிமிடெட்சீனா தேசிய பயோடெக் குழுஉலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்